Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

How we('ll) treat paroxysmal nocturnal haemoglobinuria: diving into the future.

British journal of haematology - 1 Jan 2022

Risitano Antonio Maria, Peffault de Latour Régis

Abstract excerpt

Paroxysmal nocturnal haemoglobinuria (PNH) is characterized by complement-mediated intravascular haemolysis, severe thrombophilia and bone marrow failure. While for patients with bone marrow failure the treatment follows that of immune-mediated aplastic anaemia, that of classic, haemolytic PNH is based on anti-complement medication. The anti-C5 monoclonal antibody eculizumab has revolutionized treatment,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disease Susceptibility
Share to Algorithms
Share to Clinical Decision-Making

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Combined Modality Therapy

Share to Disease Management

Share to Hemoglobinuria, Paroxysmal

Share to Prognosis

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 34355382
DOI: 10.1111/bjh.17753
PMCID: PMC9291300

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

How we('ll) treat paroxysmal nocturnal haemoglobinuria: diving into the future.PMID 34355382Read ↗

Complement inhibition in paroxysmal nocturnal hemoglobinuria: From biology to therapySemantic proximity Read ↗

Paroxysmal Nocturnal Hemoglobinuria: Unraveling Its Molecular Pathogenesis and Advancing Targeted Therapeutic StrategiesSemantic proximity Read ↗

Monitoring of patients with paroxysmal nocturnal hemoglobinuria on a complement inhibitorSemantic proximity Read ↗

Recent advances in the pathogenesis and treatment of paroxysmal nocturnal hemoglobinuriaSemantic proximity Read ↗

Paroxysmal Nocturnal Hemoglobinuria: Biology and TreatmentSemantic proximity Read ↗

With complements: C3 inhibition in the clinicSemantic proximity Read ↗

Management of paroxysmal nocturnal hemoglobinuria in the era of complement inhibitory therapy.Semantic proximity Read ↗

[Paroxysmal nocturnal hemoglobinuria: from physiopathology to treatment].Semantic proximity Read ↗

The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal HemoglobinuriaSemantic proximity Read ↗

Current status and perspectives of hematopoietic cell transplantation in patients with paroxysmal nocturnal hemoglobinuriaSemantic proximity Read ↗

Protein therapeutics and their lessons: Expect the unexpected when inhibiting the multi‐protein cascade of the complement systemSemantic proximity Read ↗

Complement C5 inhibitor crovalimab for the treatment of paroxysmal nocturnal hemoglobinuria.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.